RCS - N4 Pharma PLC - Investor Webinar

N4 PharmaAnnouncement

07/02/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250207:nRSG2346Wa&default-theme=true

RNS Number : 2346W  N4 Pharma PLC  07 February 2025

 

 

7 February 2025

N4 Pharma plc

 

("N4 Pharma" or the "Company")

 

Investor Webinar

 

N4 Pharma plc (AIM: N4P), the biotech developing Nuvec®, its proprietary gene
delivery system to enable advanced therapies for cancer and other diseases, is
pleased to announce that Nigel Theobald, Chief Executive Officer will be
presenting at the ShareSoc Discovery Company Webinar on Tuesday, 25 February
2025 at 5.00 pm.

 

Further details of the event and registration form are available here:

https://www.sharesoc.org/events/discovery-company-webinar-25-february-25/
(https://www.sharesoc.org/events/discovery-company-webinar-25-february-25/)

 

- Ends -

 

For more information please contact:

 

 N4 Pharma plc

 Nigel Theobald, Chief Executive Officer                      Via N4 Pharma Investor Hub

 Luke Cairns, Executive Director                              Sign up at investors.n4pharma.com (https://investors.n4pharma.com/)
 Investor questions on this announcement                      https://investors.n4pharma.com/link/0rJx8y

                                                            (https://investors.n4pharma.com/link/0rJx8y)
 We also invite investors to ask questions

 on this announcement via our investor hub
 SP Angel Corporate Finance LLP                               Tel: +44 (0) 20 3470 0470

 Nominated Adviser and Joint Broker

 Matthew Johnson/Jen Clarke (Corporate Finance)

 Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking)
 Turner Pope Investments (TPI) Limited                        Tel: +44 (0) 20 3657 0050

 Joint Broker

 Andy Thacker/James Pope
 Northstar Communications Limited                             Tel: +44 (0) 113 730 3896

 Investor Relations

 Sarah Hollins

 

About N4 Pharma

N4 Pharma is a biotech company developing Nuvec®, its proprietary gene
delivery system, to enable advanced therapies for cancer and other diseases.

 

RNA therapeutics are set to impact the treatment of a wide range of diseases
and Nuvec® has several key advantages for RNA gene delivery including the
ability to deliver multiple RNA therapies in a single particle, ease of
manufacturing, protection of the RNA payload to allow for oral delivery, no
unwanted immune response and excellent stability and storage.

 

N4 Pharma is building out its preclinical data set and working towards
first-in-human clinical data to support significant licensing deals for its
Nuvec® platform with gene therapy partners.

 

N4 Pharma's lead programme, N4 101, is an oral anti-inflammatory product for
inflammatory bowel disease (IBD) which serves as a proof-of-concept programme
showcasing all the benefits of the Nuvec® platform. With an estimated 10
million people globally suffering from Crohn's disease and ulcerative colitis,
the IBD treatment market was worth $20.4bn in 2023 and is expected to grow by
a CAGR of 3.9% to over $27.6bn by 2030, driven by both increased incidences of
the disease and development of new treatments.

 

For further information on the Company visit www.n4pharma.com
(http://www.n4pharma.com) or sign up at
https://investors.n4pharma.com/auth/signup
(https://investors.n4pharma.com/auth/signup) .

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAEASAKEEPSEFA